SURMOUNT-1—Results of The First Phase 3 Obesity Trial with The Novel GIP/GLP-1 Receptor Agonist Tirzepatide
Achieving the Unachievable—Will Achievement of Normoglycemia Become a Treatment Goal in T2D?
Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Dual Agonist, Was Safe and Well Tolerated and Showed Dose-Dependent Body Weight Loss over Four Weeks in Healthy Subjects
Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study
Eligibility and Utilization of SGLT2i and GLP1-RA in T2D by Cardiovascular and Renal Indications
Expert overviews in other languages